CAJ | 학술논문

目的研究探讨乳腺癌组织中VEGF-C及癌周淋巴管密度(poritumoral lymph vesselsdensity,PLVD)的表达和分布情况及其临床病理学特征,初步探讨其与乳腺癌相关淋巴水肿(breastcancer-related lymphoedema,BCRL)发生间的关系. 方法应用免疫组化技术检测47例乳腺癌组织中VEGF-C及VEGFR-3,观察乳腺癌组织中VEGF-C的表达情况并计数,检测患者双侧上肢周径,判断有无水肿并分级.结果 47例乳腺癌组织中VEGF-C阳性表达者33例,VEGF-C阳性组的PLVD(30.39±10.46)较阴性组(23.16±11.67)明显增高(P<0.05).癌组织内VEGF-C半定量评分与PLVD呈正相关(r=0.334).淋巴结转移组VEGF-C的阳性表达率(42.55%)及半定量评分(3.68±1.59)均高于未转移组(27.66%,2.48±2.31)(P<0.05);淋巴结转移组PLVD高于未转移组(32.12±10.29 vs.24.82±11.06),P<0.05.47例患者中一年内发生BCRL者17例,一年后仍有BCRL的8例.VEGF-C阴性组发生水肿者(5/14)较阳性组(3/33)增加(P<0.05).结论 VEGF-C在乳腺癌组织中有较高的阳性表达率,并且与PLVD呈正相关.乳腺癌组织中VEGF-C高表达可减少BCRL发生的机会.
목적 연구탐토유선암조직중VEGF-C급암주림파관밀도(poritumoral lymph vesselsdensity,PLVD)적표체화분포정황급기림상병이학특정,초보탐토기여유선암상관림파수종(breastcancer-related lymphoedema,BCRL)발생간적관계. 방법응용면역조화기술검측47례유선암조직중VEGF-C급VEGFR-3,관찰유선암조직중VEGF-C적표체정황병계수,검측환자쌍측상지주경,판단유무수종병분급.결과 47례유선암조직중VEGF-C양성표체자33례,VEGF-C양성조적PLVD(30.39±10.46)교음성조(23.16±11.67)명현증고(P<0.05).암조직내VEGF-C반정량평분여PLVD정정상관(r=0.334).림파결전이조VEGF-C적양성표체솔(42.55%)급반정량평분(3.68±1.59)균고우미전이조(27.66%,2.48±2.31)(P<0.05);림파결전이조PLVD고우미전이조(32.12±10.29 vs.24.82±11.06),P<0.05.47례환자중일년내발생BCRL자17례,일년후잉유BCRL적8례.VEGF-C음성조발생수종자(5/14)교양성조(3/33)증가(P<0.05).결론 VEGF-C재유선암조직중유교고적양성표체솔,병차여PLVD정정상관.유선암조직중VEGF-C고표체가감소BCRL발생적궤회.
Objective To study the distribution and clinicopathological characteristics between VEGF-C and pefitumoral lymph vessels density(PLVD) in breast cancer tissue, and to investigate the development and the mechanism of breast cancer-related lymphoedema (BCRL). Methods VEGF-C and VEGFR-3 were detected by using immunohistochemical technique for the detection of VEGF-C and its receptor VEGFR-3 in forty-seven breast cancer specimens. We measured the patients' circumferences of bilateral upper limbs to determine whether there was lymphoedema and made classification in the follow-ups. Results VEGF-C was positive in 33 out of 47 cases. PLVD significantly increased in VEGF-C positive groups (30.39±10. 46) than in negative groups (23.16±11.67) (P<0.05). VEGF-C semi-quantitative score was in a positive correlation with PLVD (r=0.334). The positive expression rate (42.55%) and semi-quantitative score (3.68±1.59) of VEGF-C increased in the lymph node positive group than in the negative group, PLVD increased in the lymph node positive group compared with that in negative group (32.12±10.29 vs. 24.82±11.06), P<0.05. The risk of lymphoedema increased in the VEGF-C negative group (5/14) compared with that in the positive group (3/33) (P<0.05). Conclusion VEGF-C has a high rate of positive expression in breast cancer, and is positively correlated with PLVD. High expression of VEGF-C can reduce the risk of BCRL in breast cancer.